Gossamer Bio, Inc. (GOSS): Operating Cash Flow
-$171.27M
Year ended 2025-12-31
-$162.63M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$171.27M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$3.47M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$159.16M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$187.03M | n/m | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | -$188.89M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$176.36M | n/m | 2023-03-17, From 2020-01-01 |
| 2019-12-31 | -$144.83M | n/m | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | -$51.04M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$5.75M | n/a | 2020-03-24, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.27M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $57.67M | -68.7% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $110.19M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$204.88M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$52.43M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.93M | n/m |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$4.99M | n/m |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | -$33.54M | n/m |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗